Full Text
A Canadian Cost Impact Analysis Comparing Maintenance Therapy with Bortezomib Versus Lenalidomide in Multiple Myeloma Patients Ineligible for Stem Cell Transplant

Abstract

Authors

J. Shustik J. Tay S. Hollmann R. LeBlanc

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×